Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Morning coffee may give athletes a real edge, study finds

NCT ID NCT07466628

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether taking 300 mg of caffeine (about 2-3 cups of coffee) can help healthy young men perform better on muscle strength and thinking tasks in the morning. Fifteen low-caffeine users completed strength exercises and cognitive tests after taking caffeine, a placebo, or no pill. The goal was to see if caffeine can counteract the natural morning dip in performance, which could help athletes who train or compete early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

15 people

The number who actually took part.

Started

Nov 2024

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Healthy adults * 18-35 years old * Injury-free * ≥ 2 years of weight/strength training experience * Not receiving any pharmacological treatment (including non-steroidal anti-inflammatory drugs, NSAIDs) throughout the study period * Low habitual caffeine consumers (≤ 150mg per day) * No preference to training regarding time-of-day Exclusion criteria: * Depressed mood (from the Beck depression inventory) * Poor sleep quality (a Pittsburgh sleep quality index global score \>5 * Recent shiftwork or travel across multiple time-zones * 'Extreme' chronotype (assessed via the Composite Morningness Questionnaire * Risk factors and/or symptoms of cardiovascular disease. * Minimal knowledge of the effects of time-of-day or time-since-sleep on human performance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Caffine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tom Reilly Building (LJMU)

    Liverpool, Merseyside, L3 3AF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.